The FDA cleared Novartis gene therapy Zolgensma in infants with the genetic disease SMA. Its price tag, $2.1 million, can be paid out over five years and comes with a partial performance-based rebate.
A postmortem on the Entresto launch reveals some lessons in value-based contracting.
The acquisition of Vertical Health’s clinician-oriented brands is consistent with and extends an existing Remedy strategy, said the CEO.
Execs speaking at a technology conference on Tuesday refuted the notion that pharma is behind other industries in adapting to the digital age.
Asked about the impending shifts, media mavens said that what makes CBS the pharma network of choice doesn’t change with these lineup tweaks.
Yesterday’s Insys verdict sends a strong message: Marketing abuses once excused with a mere monetary fine could now result in jail time, and it’s not only drug makers taking heat.
As VP of medical sales and education for medical cannabis maker Canopy Growth, Daley spoke about how the firm is upping doctors’ comfort level with medical marijuana, and gave a preview of her closing keynote for the MM&M Transforming Healthcare conference.
If increasing transparency is the most effective act healthcare companies can take to restore trust, is pharma blowing a big opportunity around drug pricing disclosure?
The argument about PBM rebates masks the real opportunity: to improve patients’ experience at the point of care.
Priscilla Beal, global head of digital health engagement for Bayer, spoke about the tie-ups between drugmakers and health-tech startups and gave a preview of her keynote for the MM&M Transforming Healthcare conference.
